Sofosbuvir
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | SOVALDI | — | 2017-04-07 – 2019-08-28 | fda.gov ↗ |
| Approved | EU (EMA) | Sovaldi | — | 2014-01-16 | europa.eu ↗ |
| Approved | US (FDA) | SOVALDI | — | 2013-12-06 | fda.gov ↗ |
Trials 217 · started per year
Also used as a comparator or background therapy in 46 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03882307 Comparator | Oct → Nov 2022 | chronic hepatitis C virus infection | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT03188276 Comparator | Feb 2016 → May 2017 | chronic hepatitis C virus infection | Third Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03005210 Comparator | Nov 2016 | — | Genuine Research Center, Egypt | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT03146741 Background | May 2017 → Sep 2019 | heart failure | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1/2 | NCT04387539 Comparator | Mar → Oct 2017 | chronic hepatitis C virus infection | Beni-Suef University | Completed | No outcome recorded |
| Phase 1/2 | NCT04391985 Comparator | Mar → Oct 2017 | chronic hepatitis C virus infection | Beni-Suef University | Completed | No outcome recorded |
| Phase 1/2 | NCT04382339 Comparator | Mar → Nov 2015 | chronic hepatitis C virus infection | Beni-Suef University | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT04561063 Comparator | Dec 2020 → Feb 2022 | COVID-19 | University of Witwatersrand, South Africa | Completed | No outcome recorded |
| Phase 2 | NCT05091008 Comparator | Mar 2018 → Aug 2019 | chronic hepatitis C virus infection | Mansoura University Children Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02551861 Comparator | Dec 2015 → Jun 2016 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 2 | NCT02541409 Comparator | Sep 2015 → Dec 2016 | chronic hepatitis C virus infection | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
| Phase 2 | NCT02421211 Background | May → Nov 2015 | chronic hepatitis C virus infection | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 2 | NCT04385407 Comparator | Apr 2015 → Jul 2016 | chronic hepatitis C virus infection | Beni-Suef University | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT05616598 Comparator | Mar → Nov 2022 | hepatitis C virus infection, male infertility | Benha University | Completed | No outcome recorded |
| Phase 2/3 | NCT03480932 Comparator | Feb → Nov 2018 | chronic hepatitis C virus infection | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
| Phase 2/3 | NCT02985281 Comparator | Dec 2016 → Jun 2017 | — | National Liver Institute, Egypt | Unknown | No outcome recorded |
| Phase 2/3 | NCT04387526 Comparator | Apr 2016 → May 2017 | chronic hepatitis C virus infection | Beni-Suef University | Completed | No outcome recorded |
| Phase 2/3 | NCT02483156 Comparator | Jul → Aug 2015 | chronic hepatitis C virus infection | Egyptian Liver Hospital | Completed | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT07037277 Comparator | Jun 2025 → Dec 2026 expected | chronic hepatitis C virus infection | Atea Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06868264 Comparator | Apr 2025 → Sep 2026 expected | chronic hepatitis C virus infection | Atea Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04535869 Comparator | Dec 2020 → Apr 2021 | COVID-19 | Mansoura University | Unknown | No outcome recorded |
| Phase 3 | NCT03343444 Comparator | Apr 2017 → Nov 2018 | chronic hepatitis C virus infection | Egyptian Liver Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03186313 Comparator | Sep 2016 → May 2017 | chronic hepatitis C virus infection | Egyptian Liver Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02723084 Comparator | Apr 2016 → Jan 2017 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02639247 Background | Dec 2015 → Oct 2016 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02640157 Comparator | Dec 2015 → Oct 2016 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02576314 Comparator | May 2015 → Dec 2017 | chronic hepatitis C virus infection | Humanity and Health Research Centre | Completed | No outcome recorded |
| Phase 3 | NCT02363517 Comparator | Feb 2015 → Dec 2018 | hepatitis C virus infection, substance abuse | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT02319031 Comparator | Feb → Oct 2015 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT05467826 Background | Sep 2022 → Nov 2023 | cirrhosis of liver, hepatitis C virus infection | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT06306300 Comparator | Jul 2022 → Dec 2025 | hepatitis C virus infection | Oswaldo Cruz Foundation | Unknown | No outcome recorded |
| Phase 4 | NCT03296930 Comparator | Oct 2017 → Sep 2018 | poisoning | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT02938013 Background | Jan 2017 → Sep 2019 | HIV infectious disease, hepatitis C virus infection | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT02347345 Comparator | Nov 2016 | hepatitis C virus infection | Rockefeller University | Completed | No outcome recorded |
| Phase 4 | NCT03069001 Comparator | Jun 2015 → Mar 2016 | hepatitis C virus infection | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT02992457 Comparator | Jan 2015 → Dec 2018 | hepatitis C virus infection | Tanta University | Completed | No outcome recorded |
| Phase 4 | NCT02702739 Comparator | Jan → Dec 2015 | cirrhosis of liver | Azienda Ospedaliera San Camillo Forlanini | Completed | No outcome recorded |
| Phase 4 | NCT02214420 Comparator | Oct 2014 → Jun 2016 | hepatitis C virus infection | SC Liver Research Consortium, LLC | Completed | No outcome recorded |
| Phase 4 | NCT03133065 Comparator | Sep 2014 → Dec 2016 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT02168361 Background | Dec 2013 → Dec 2014 | chronic hepatitis C virus infection | Center For Hepatitis C, Atlanta, GA | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT05248919 Comparator | Jun 2023 → Sep 2027 expected | hepatitis C virus infection | Queen Mary University of London | Enrolling by invitation | No outcome recorded |
| — | NCT03669835 Background | Mar 2018 → Sep 2019 | hepatitis C virus infection | Asfendiyarov Kazakh National Medical University | Completed | No outcome recorded |
| — | NCT03549832 Comparator | Jan 2018 → Jan 2019 | hepatitis C virus infection | Assiut University | Completed | No outcome recorded |
| — | NCT03481036 Comparator | Jun 2016 → Dec 2020 | chronic hepatitis C virus infection | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| — | NCT03547895 Comparator | Jun 2015 → May 2016 | cirrhosis of liver | Zagazig University | Completed | No outcome recorded |
| — | NCT02464631 Comparator | Jun 2015 → Dec 2016 | hepatitis C induced liver cirrhosis | Institute of Liver and Biliary Sciences, India | Terminated | No outcome recorded |
Press releases naming this drug 71 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-03-19 | Gilead Sciences | U.S. Food And Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection gilead.com ↗ |
| 2019-12-20 | Gilead Sciences | China National Medical Products Administration Approves Vosevi® (Sofosbuvir, Velpatasvir and Voxilaprevir) for People With Chronic Hepatitis C Infection Who Require Re-Treatment gilead.com ↗ |
| 2019-01-08 | Gilead Sciences | Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) gilead.com ↗ |
| 2018-12-04 | Gilead Sciences | China’s National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6 gilead.com ↗ |
| 2018-09-24 | Gilead Sciences | Gilead Subsidiary to Launch Authorized Generics of Epclusa® (Sofosbuvir/Velpatasvir) and Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C gilead.com ↗ |
| 2018-05-30 | Gilead Sciences | China Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir), Gilead’s Pan-Genotypic Treatment for Chronic Hepatitis C Virus Infection gilead.com ↗ |
| 2017-09-25 | Gilead Sciences | China Food and Drug Administration Approves Gilead’s Sovaldi® (Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Infection gilead.com ↗ |
| 2017-08-01 | Gilead Sciences | U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV gilead.com ↗ |
| 2017-07-28 | Gilead Sciences | European Commission Grants Marketing Authorization for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Genotypes of Chronic Hepatitis C gilead.com ↗ |
| 2017-07-18 | Gilead Sciences | U.S. Food and Drug Administration Approves Gilead’s Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-Treatment of Adults with Chronic Hepatitis C Virus gilead.com ↗ |
| 2017-06-23 | Gilead Sciences | European CHMP Adopts Positive Opinion for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes gilead.com ↗ |
| 2017-04-21 | Gilead Sciences | Gilead Announces Scientific Presentations Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient Populations With HCV Infection gilead.com ↗ |
| 2017-04-07 | Gilead Sciences | U.S. FDA Approves New Indications for Harvoni® and Sovaldi® in Pediatric Patients 12 Years and Older with Chronic Hepatitis C Infection gilead.com ↗ |
| 2017-01-20 | Gilead Sciences | European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) gilead.com ↗ |
| 2016-12-08 | Gilead Sciences | Gilead Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen Sofosbuvir/Velpatasvir/Voxilaprevir gilead.com ↗ |
| 2016-10-20 | Gilead Sciences | Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir and Voxilaprevir in Treatment-Naïve and Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients gilead.com ↗ |
| 2016-07-08 | Gilead Sciences | European Commission Grants Marketing Authorization for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C gilead.com ↗ |
| 2016-06-28 | Gilead Sciences | U.S. Food and Drug Administration Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C gilead.com ↗ |
| 2016-05-27 | Gilead Sciences | European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C gilead.com ↗ |
| 2016-04-16 | Gilead Sciences | Gilead Announces Multiple Scientific Presentations Demonstrating Broad Utility of Sofosbuvir-Based Hepatitis C Therapies gilead.com ↗ |
| 2016-02-16 | Gilead Sciences | U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease gilead.com ↗ |
| 2016-01-04 | Gilead Sciences | Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir for Treatment of All Genotypes of Chronic Hepatitis C Infection gilead.com ↗ |
| 2015-12-04 | Gilead Sciences | European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for the Treatment of Hepatitis C gilead.com ↗ |
| 2015-11-14 | Gilead Sciences | Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies gilead.com ↗ |
| 2015-11-12 | Gilead Sciences | U.S. FDA Approves New Indications for Harvoni®, Gilead’s Once-Daily Single Tablet Regimen for Chronic Hepatitis C gilead.com ↗ |
| 2015-10-28 | Gilead Sciences | Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for Treatment of All Six Genotypes of Hepatitis C gilead.com ↗ |
| 2015-09-21 | Gilead Sciences | Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes gilead.com ↗ |
| 2015-07-03 | Gilead Sciences | Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Harvoni®, the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C gilead.com ↗ |
| 2015-04-25 | Gilead Sciences | Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5 gilead.com ↗ |
| 2015-04-23 | Gilead Sciences | Gilead’s Harvoni and Sovaldi Demonstrate Efficacy and Safety among Chronic Hepatitis C Patients with Advanced Liver Disease gilead.com ↗ |
| 2015-04-23 | Gilead Sciences | Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C gilead.com ↗ |
| 2015-03-26 | Gilead Sciences | Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the Treatment of Genotype 2 Chronic Hepatitis C gilead.com ↗ |
| 2015-02-26 | Gilead Sciences | Gilead Announces SVR12 Rates From Phase 3 Study Evaluating Harvoni® for the Treatment of Chronic Hepatitis C in Patients Co-Infected With HIV gilead.com ↗ |
| 2014-11-18 | Gilead Sciences | European Commission Grants Marketing Authorization for Gilead’s Harvoni®▼ (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4 gilead.com ↗ |
| 2014-11-11 | Gilead Sciences | Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C gilead.com ↗ |
| 2014-11-11 | Gilead Sciences | Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease and Those Who Failed Prior Treatment gilead.com ↗ |
| 2014-10-16 | Gilead Sciences | Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C gilead.com ↗ |
| 2014-10-10 | Gilead Sciences | U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C gilead.com ↗ |
| 2014-09-26 | Gilead Sciences | European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults gilead.com ↗ |
| 2014-09-24 | Gilead Sciences | Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection gilead.com ↗ |
| 2014-06-27 | Gilead Sciences | Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C gilead.com ↗ |
| 2014-06-15 | Gilead Sciences | Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan gilead.com ↗ |
| 2014-04-11 | Gilead Sciences | Gilead’s Sovaldi® Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease gilead.com ↗ |
| 2014-04-10 | Gilead Sciences | Gilead Announces Results from Study of Sovaldi® for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy gilead.com ↗ |
| 2014-04-10 | Gilead Sciences | Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C gilead.com ↗ |
| 2014-04-07 | Gilead Sciences | Gilead Announces U.S. FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Chronic Hepatitis C Genotype 1 Infection gilead.com ↗ |
| 2014-04-02 | Gilead Sciences | Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan gilead.com ↗ |
| 2014-03-27 | Gilead Sciences | European Medicines Agency Validates Gilead’s Marketing Application for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Chronic Hepatitis C Infection gilead.com ↗ |
| 2014-02-10 | Gilead Sciences | Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C gilead.com ↗ |
| 2014-01-17 | Gilead Sciences | European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection gilead.com ↗ |
| 2013-12-18 | Gilead Sciences | Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients gilead.com ↗ |
| 2013-12-16 | Gilead Sciences | Health Canada Issues Notice of Compliance for Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C gilead.com ↗ |
| 2013-12-06 | Gilead Sciences | U.S. Food and Drug Administration Approves Gilead’s Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C gilead.com ↗ |
| 2013-11-22 | Gilead Sciences | European CHMP Adopts Positive Opinion for Gilead Sciences’ Sovaldi® for the Treatment of Chronic Hepatitis C Infection gilead.com ↗ |
| 2013-11-02 | Gilead Sciences | Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV gilead.com ↗ |
| 2013-11-02 | Gilead Sciences | Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation gilead.com ↗ |
| 2013-11-02 | Gilead Sciences | Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients gilead.com ↗ |
| 2013-10-25 | Gilead Sciences | FDA Advisory Committee Supports Approval of Gilead’s Sofosbuvir for Chronic Hepatitis C Infection gilead.com ↗ |
| 2013-06-07 | Gilead Sciences | Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir for the Treatment of Hepatitis C gilead.com ↗ |
| 2013-05-21 | Gilead Sciences | European Medicines Agency Validates Gilead’s Marketing Application for Sofosbuvir for the Treatment of Hepatitis C gilead.com ↗ |
| 2013-04-23 | Gilead Sciences | Data from Phase 3 Studies of Gilead’s Sofosbuvir for Hepatitis C To Be Presented at 48th Annual EASL Meeting; Findings Published Online Today in The New England Journal of Medicine gilead.com ↗ |
| 2013-04-08 | Gilead Sciences | Gilead Submits New Drug Application to U.S. FDA for Sofosbuvir for the Treatment of Hepatitis C gilead.com ↗ |
| 2013-03-26 | Gilead Sciences | Gilead Announces Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients gilead.com ↗ |
| 2013-02-19 | Gilead Sciences | Gilead’s Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study gilead.com ↗ |
| 2013-02-04 | Gilead Sciences | Gilead Announces Sustained Virologic Response Rates from Two Phase 3 Studies of Sofosbuvir for Hepatitis C gilead.com ↗ |
| 2012-11-27 | Gilead Sciences | Gilead Announces Sustained Virologic Response Rate of 78% From Phase 3 Study of Sofosbuvir for Genotype 2/3 Hepatitis C Infected Patients gilead.com ↗ |
| 2012-11-10 | Gilead Sciences | Gilead Announces 100 Percent Sustained Virologic Response Rate (SVR4) for an Interferon-Free Regimen of Sofosbuvir (GS-7977), GS-5885 and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C Infected Patients gilead.com ↗ |
| 2012-04-19 | Gilead Sciences | Gilead Announces Sustained Virologic Response Data for 12-Week Regimen of GS-7977 Plus Pegylated Interferon and Ribavirin in Genotype 1 Hepatitis C Patients gilead.com ↗ |
| 2012-04-19 | Gilead Sciences | Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Na ïve Hepatitis C Patients gilead.com ↗ |
| 2012-04-19 | Gilead Sciences | Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naïve Hepatitis C Patients gilead.com ↗ |
| 2012-04-19 | Bristol-Myers Squibb | All-Oral Combination of Investigational Hepatitis C (HCV) Compounds Daclatasvir and GS-7977 Achieved Sustained Virologic Response (SVR4) in 100% of Genotype 1 and 91% of Genotype 2 and 3 Treatment-Naïve Patients in Phase II Study bms.com ↗ |
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 284 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sofosbuvir | “This study will evaluate efficacy of ledipasvir/sofosbuvir (LDV/SOF) and safety and tolerability of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide...” NCT02707601 ↗252“The primary objective of this study is to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir/velpatasvir (Epclusa®; SOF/VEL) with ribavirin (RBV) for...” NCT02300103 ↗ “This study is to evaluate the antiviral efficacy, safety, and tolerability of combination therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) +...” NCT02226549 ↗ “Comparative randomized, single dose, three way three sequence two treatment partial replicate crossover open-label study to determine the bioequivalence of Sofosbuvir from...” NCT03062423 ↗ “Chinese patients with chronic HCV genotype 1b infection without cirrhosis were randomly allocated by a computer program to one of three treatment groups (sofosbuvir,...” PMID 27917405 ↗ Jul 2016 “After taking tenofovir alafenamide/emtricitabine for 12 weeks, participants will then start taking ledipasvir 90 mg/sofosbuvir 400 mg (Harvoni) in combination with the...” NCT03126370 ↗ “For hepatitis virus C genotype 1: sofosbuvir 400 mg + lepidavir 90 mg for 12 weeks OR sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks; For hepatitis virus C genotypes 2 and...” NCT03669835 ↗ “Participants will be treated with the pan-genotypic therapeutic regimen "single-pill daily," at a fixed dose and duration: sofosbuvir/velpatasvir 400/100 mg (Epclusa, Gilead...” NCT06306300 ↗ “patients with HCV genotype 2 were randomly assigned in a 1:1 ratio to receive sofosbuvir-velpatasvir, in a once-daily, fixed-dose combination tablet (134 patients), or...” PMID 26575258 ↗ Nov 2015 “This study will evaluate the antiviral efficacy of combination therapy with sofosbuvir (SOF) plus ribavirin (RBV) for 48 weeks in adults with compensated and decompensated...” NCT01687257 ↗ “determine the bioequivalence of Sofosbuvir from Heterosofir 400 mg F.C.T (Pharmed Healthcare Co., Egypt) versus Sovaldi 400 mg F.C.T (Gilead Sciences, Ireland) in Healthy Human...” NCT02491450 ↗ “Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per...” NCT03146741 ↗ “Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease” NCT02691728 ↗ “Sofosbuvir (SOVALDI®) is a nucleotide analog directed against HCV NS5B polymerase, clinically approved with potent antiviral effects on the hepatitis C virus with several genotypes21.” NCT04468087 ↗ “This study aims to evaluate the efficacy and safety of DCV plus sofosbuvir (SOF) with or without ribavirin (RBV) for treatment of Egyptian participants infected with HCV GT4.” NCT04387526 ↗ “At 20 sites, 37 individuals with chronic HCV infection of any genotype and compensated cirrhosis received sofosbuvir-velpatasvir (400 mg/100 mg) daily for 12 weeks.” PMID 35802063 ↗ Aug 2022 “voxilaprevir 100 mg plus sofosbuvir (SOF)/velpatasvir (VEL) (400/100 mg) fixed-dose combination (FDC)on Days 2 and 3 after either a light or moderate-fat meal” NCT02185794 ↗ “We assessed the efficacy and safety of the NS5B polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir for HCV in patients coinfected with HIV-1.” PMID 28369210 ↗ Jul 2017 “Ledipasvir/sofosbuvir is a two-drug, fixed-dose combination tablet approved in the USA, European Union, and Japan for chronic genotype 1 HCV infection.” PMID 27198664 ↗ May 2016 “Relapse occurred post treatment in a single case of a non-cirrhotic male with genotype 3, who was treated with sofosbuvir/velpatasvir for 6 weeks.” PMID 33082372 ↗ Oct 2020 “a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).” NCT03222531 ↗ “For adolescents aged 12-17 years, the safety and efficacy of the fixed-dose combination sofosbuvir and ledipasvir for genotype 1 or 4 infection” NCT03764345 ↗ “Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.” PMID 26551051 ↗ Nov 2015 “Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.” PMID 23982366 ↗ Aug 2013 “One hundred patients aged 12-17 years received a combination tablet of 90 mg ledipasvir and 400 mg sofosbuvir once daily for 12 weeks.” PMID 27997679 ↗ Jun 2017 “Epclusa (Sofosbuvir/Velpatasvir 400mg/100mg) course initiated at same day of visit following a +ve HCV RNA result from the POC test.” NCT05264558 ↗ “Experienced participants who had HCV GT4 infection were treated with Sofosbuvir/Simeprevir/Daclatasvir/Ribavirin (SOF/SMV/DCV/RBV)” NCT04387539 ↗ “In this study, we evaluated the efficacy and safety of sofosbuvir/velpatasvir for 12 weeks in patients from Russia and Sweden.” PMID 30499360 ↗ Nov 2018 “Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients” NCT04391985 ↗ “Patients were given ledipasvir (90 mg) plus sofosbuvir (400 mg) as a fixed-dose combination tablet once daily for 6 weeks.” PMID 28029529 ↗ Oct 2016 “the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857” PMID 27486034 ↗ Jul 2016 “53 PATIENTS were treated after 6 months of transplantation with sofosbuvir 400mg and weight based ribavirin for 24 weeks.” NCT03133065 ↗ “Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks.” NCT02480166 ↗ “Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection” NCT02175758 ↗ “Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection” NCT03074331 ↗ “Patients self-administered a combined sofosbuvir (400 mg) and velpatasvir (100 mg) tablet once daily for 12 weeks.” PMID 30555048 ↗ Dec 2018 “Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC)” NCT04211909 ↗ “treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 12 weeks” NCT03118843 ↗ “One capsule of Harvoni/ ledipasvir, 90 mg + sofosbuvir, 400 mg administered daily for 8, 12, or 24 weeks” NCT03118674 ↗ “Patients with HBV and genotype-1 HCV received 90 mg ledipasvir and 400 mg sofosbuvir daily for 12 weeks.” PMID 27367295 ↗ Jul 2016 “the hepatitis C virus NS5A inhibitor ledipasvir and the NS5B nucleotide polymerase inhibitor sofosbuvir” PMID 25863559 ↗ Apr 2015 “sofosbuvir (SOF) with pegylated interferon (PegINF)/ribavirin (RBV) for chronic HCV GT4 participants” NCT04382339 ↗ “Patients weighing 35 kg or more will receive the adult dose: ledipasvir (90 mg)/sofosbuvir (400 mg).” NCT03743727 ↗ “Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg” NCT03483987 ↗ “Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily” NCT01565889 ↗ “the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir once daily” PMID 26569658 ↗ Nov 2015 “the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor velpatasvir.” PMID 28390869 ↗ Apr 2017 “All patients received 12 weeks of treatment that included 400 mg of sofosbuvir once daily.” PMID 26551263 ↗ Nov 2015 “Treatment is: 1 tablet SOF/VEL (400 mg sofosbuvir/100 mg velpatasvir) daily x 12 weeks.” NCT03987503 ↗ “the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir” PMID 26571066 ↗ Nov 2015 “the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir” PMID 26575258 ↗ Nov 2015 “1 whole or half tablet sofosbuvir and 1 whole or half tablet daclatasvir per day” NCT03080415 ↗ “Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.” PMID 28564569 ↗ Jun 2017 “Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir” NCT04039958 ↗ “Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR\>30” NCT03702218 ↗ “Sofosbuvir (400mg/day) and Velpatasvir(100mg/day) for 12 weeks or 24 weeks” NCT05248919 ↗ “patients received once daily for 12 weeks either sofosbuvir-velpatasvir” PMID 38644678 ↗ Apr 2024 “ASC18：ravidasvir and sofosbuvir fixed Dose Combination 200 mg/400 mg” NCT04358523 ↗ “Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.” PMID 26196665 ↗ Jul 2015 “Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.” NCT01604850 ↗ “Sofosbuvir (SOF) 400 mg tablet is administered orally once daily” NCT02480686 ↗ “Sofosbuvir (SOF) 400 mg tablet administered orally once daily.” NCT02482077 ↗ “Sofosbuvir (SOF) 400 mg tablet administered orally once daily” NCT01682720 ↗ “Sofosbuvir (SOF) 400 mg tablet administered orally once daily” NCT01808248 ↗ “Sofosbuvir (SOF) 400 mg tablet administered orally once daily” NCT01667731 ↗ “Sofosbuvir (SOF) 400 mg tablet administered orally once daily” NCT01838590 ↗ “Sofosbuvir (SOF) 400 mg tablet administered orally once daily” NCT01896193 ↗ “Sofosbuvir (SOF) 400 mg tablet administered orally once daily” NCT01542788 ↗ “Sofosbuvir (SOF) 400 mg tablet administered orally once daily” NCT01713283 ↗ “Sofosbuvir (SOF) 400 mg tablet administered orally once daily” NCT02932293 ↗ “1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir” NCT03005210 ↗ “sofosbuvir /velpatasvir (SOF/VEL) fixed-dose combination” NCT02781571 ↗ “Sofosbuvir (SOF) tablets administered orally once daily” NCT01260350 ↗ “Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV)” NCT02673489 ↗ “Sofosbuvir (SOF) 400 mg administered orally once daily” NCT03794258 ↗ “sofosbuvir (SOF) plus ribavirin (RBV) for 24 weeks” NCT01958281 ↗ “Sofosbuvir (SOF)+ Daclatasvir (DCV) for 12-weeks” NCT03488485 ↗ “the nucleotide polymerase inhibitor sofosbuvir” PMID 27486033 ↗ Jul 2016 “sofosbuvir/velapatasvir combination (Epclusa)” NCT03520660 ↗ “SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead)” NCT03249194 ↗ “1 tablet contains 400 mg sofosbuvir” NCT02953535 ↗ “1 tablet contains 400 mg sofosbuvir” NCT02605798 ↗ “sofosbuvir (SOF) + ribavirin (RBV)” NCT02738333 ↗ “Sofosbuvir and Daclatasvir” NCT03481036 ↗ “sofosbuvir (SOF; GS-7977)” NCT01625338 ↗ “Sofosbuvir + Ribavirin” NCT02469012 ↗ “Drug: Sofosbuvir” NCT02074514 ↗ “Drug: Sofosbuvir” NCT02168361 ↗ |
| Known as | GS-7977 | “Sofosbuvir (formerly known as GS-7977) is a direct-acting nucleotide polymerase inhibitor that is being developed as an oral drug for the treatment of chronic HCV infection” NCT02804386 ↗ |
| Known as | Harvoni | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02825212 ↗ |
| Known as | Heterosofir | “determine the bioequivalence of Sofosbuvir from Heterosofir 400 mg F.C.T (Pharmed Healthcare Co., Egypt) versus Sovaldi 400 mg F.C.T (Gilead Sciences, Ireland) in Healthy Human...” NCT02491450 ↗ |
| Known as | Ledipasvir-Sofosbuvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05091008 ↗ |
| Known as | LPV-SOF | “The availability of interferon (IFN)-free HCV Direct Acting Antiviral (DAA) antiviral therapy such as Ledipasvir-Sofosbuvir (LPV-SOF) allows for broad provision of treatment...” NCT02660905 ↗ |
| Known as | PSI-7977 | “Sofosbuvir is also known as GS-7977 or PSI-7977.” NCT02125500 ↗ |
| Known as | Psi-7977, gs-7977 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1259059 ↗ |
| Known as | SOF | “This study is to evaluate the antiviral efficacy, safety, and tolerability of combination therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) +...” NCT02226549 ↗62“The proposed study will quantify hepatic improvement and antiviral efficacy of the open-label interferon-free combination of 12 weeks of simeprevir (SMV, Simeprevir),...” NCT02455167 ↗ “METHODS: A subanalysis of efficacy and safety for a daclatasvir (DCV) and sofosbuvir (SOF) regimen, with or without ribavirin (RBV), was undertaken in HIV-HCV-coinfected...” PMID 27845298 ↗ Nov 2016 “This phase III study (ALLY-3; ClinicalTrials.gov: NCT02032901) evaluated the 12-week regimen of daclatasvir (DCV; pangenotypic nonstructural protein [NS]5A inhibitor) plus...” PMID 25614962 ↗ Mar 2015 “This study will evaluate the antiviral efficacy of combination therapy with sofosbuvir (SOF) plus ribavirin (RBV) for 48 weeks in adults with compensated and decompensated...” NCT01687257 ↗ “containing the NS5B polymerase inhibitor sofosbuvir (SOF) 90 mg and the NS5A inhibitor ledipasvir (LDV) 400mg, marked a new era of IFN and ribavirin free, directly acting...” NCT02683005 ↗ “The C-ISLE study assessed the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) plus sofosbuvir (SOF) with and without ribavirin (RBV) in compensated cirrhotic participants...” PMID 29473975 ↗ Apr 2018 “sofosbuvir (SOF) + velpatasvir (VEL; GS-5816) with or without ribavirin (RBV) in treatment-naive adults with chronic genotype (GT) 1, 2, 3, 4, 5, or 6 hepatitis C virus (HCV) infection.” NCT01858766 ↗ “The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + velpatasvir (VEL; GS-5816) with or without ribavirin (RBV)” NCT01909804 ↗ “This study aims to evaluate the efficacy and safety of DCV plus sofosbuvir (SOF) with or without ribavirin (RBV) for treatment of Egyptian participants infected with HCV GT4.” NCT04387526 ↗ “This is a study of grazoprevir (MK-5172) + elbasvir (MK-8742) and sofosbuvir (SOF) in treatment-naive participants with chronic hepatitis C (HCV) genotype (GT) 1 or GT3.” NCT02133131 ↗ “voxilaprevir 100 mg plus sofosbuvir (SOF)/velpatasvir (VEL) (400/100 mg) fixed-dose combination (FDC)on Days 2 and 3 after either a light or moderate-fat meal” NCT02185794 ↗ “To investigate the efficacy and safety of sofosbuvir (SOF) plus daclatasvir (DCV) or simeprevir (SMV) in a randomized, open-label, noninferiority trial” PMID 29906601 ↗ Jun 2018 “The current recommendation for treating hepatitis C virus (HCV) in HIV patients includes the combination of sofosbuvir (SOF) and daclatasvir (DCV).” PMID 33930223 ↗ May 2021 “Velpatasvir (VEL) is an HCV non-structural protein 5A (NS5A) inhibitor and sofosbuvir (SOF) is an HCV NS5B nucleotide polymerase inhibitor.” NCT03250910 ↗ “Experienced participants who had HCV GT4 infection were treated with Sofosbuvir/Simeprevir/Daclatasvir/Ribavirin (SOF/SMV/DCV/RBV)” NCT04387539 ↗ “Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection” NCT03487848 ↗ “In India, four DAAs are available (sofosbuvir [SOF], daclatasvir [DCV], ledipasvir [LDV] and velpatasvir [VEL]).” NCT03483987 ↗ “sofosbuvir (SOF)/velpatasvir (VEL) ± ribavirin (RBV), glecaprevir/pibrentasvir and SOF/VEL/voxilaprevir (VOX)” NCT05467826 ↗ “Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC)” NCT04211909 ↗ “Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (RBV)” NCT02292719 ↗ “sofosbuvir (SOF) with pegylated interferon (PegINF)/ribavirin (RBV) for chronic HCV GT4 participants” NCT04382339 ↗ “Sofosbuvir (SOF) and ribavirin (RBV) will be taken orally once daily for the entire study period.” NCT02541409 ↗ “Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily” NCT01565889 ↗ “Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily” NCT02309918 ↗ “sofosbuvir (SOF)/velpatasvir (VEL; GS-5816) fixed-dose combination (FDC) for 12 weeks” NCT02671500 ↗ “voxilaprevir (VOX) plus sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC)” NCT02378935 ↗ “combined therapy ledipasvir (LDV) and sofosbuvir (SOF) for treating HCV Genotype 4” NCT03743727 ↗ “combination therapy with daclatasvir (DCV) and sofosbuvir (SOF) for 8 weeks” NCT02556086 ↗ “Sofosbuvir (SOF) 400 mg tablet is administered orally once daily” NCT02480686 ↗ “Sofosbuvir (SOF) 400 mg tablet administered orally once daily.” NCT02482077 ↗ “Sofosbuvir (SOF) 400 mg tablet administered orally once daily” NCT02470858 ↗ “Sofosbuvir (SOF) 400 mg tablet administered orally once daily” NCT01713283 ↗ “Sofosbuvir (SOF) 400 mg tablet administered orally once daily” NCT02932293 ↗ “Sofosbuvir (SOF) 400 mg tablet administered orally once daily” NCT01542788 ↗ “Sofosbuvir (SOF) 400 mg tablet administered orally once daily” NCT01838590 ↗ “Sofosbuvir (SOF) 400 mg tablet administered orally once daily” NCT01896193 ↗ “Sofosbuvir (SOF) 400 mg tablet administered orally once daily” NCT01682720 ↗ “Sofosbuvir (SOF) 400 mg tablet administered orally once daily” NCT01808248 ↗ “Includes 400 mg sofosbuvir (SOF) and 90 mg ledipasvir (LDV)” NCT02858180 ↗ “sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination” NCT02201901 ↗ “Sofosbuvir (SOF) tablets administered orally once daily” NCT01260350 ↗ “Sofosbuvir (SOF) 400 mg administered orally once daily” NCT03794258 ↗ “group 1: sofosbuvir (SOF)+ribavirin (RBV) for 24 weeks” PMID 29727383 ↗ Aug 2018 “Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV)” NCT02673489 ↗ “combination of sofosbuvir plus ledipasvir (SOF + LDP)” NCT02363517 ↗ “combination of sofosbuvir (SOF) and simeprevir (SMV)” PMID 27782373 ↗ Dec 2016 “sofosbuvir (SOF) plus ribavirin (RBV) for 24 weeks” NCT01958281 ↗ “Sofosbuvir (SOF)+ Daclatasvir (DCV) for 12-weeks” NCT03488485 ↗ “SOF 400 mg tablet administered orally once daily” NCT01826981 ↗ “Sofosbuvir (SOF)+Daclatasvir (DCV) for 12 weeks” NCT03481036 ↗ “Sofosbuvir tablet (SOF) 400 mg - once daily” NCT02483156 ↗ “sofosbuvir (SOF) + ribavirin (RBV)” NCT02201953 ↗ “sofosbuvir (SOF)/ledipasvir (LDV)” NCT01975675 ↗ “sofosbuvir/velpatasvir (SOF/VEL)” NCT06159504 ↗ “sofosbuvir (SOF; GS-7977)” NCT01625338 ↗ “Sofosbuvir (SOF)/GS-5816” NCT02336139 ↗ “sofosbuvir (SOF)” PMID 29546644 ↗ Mar 2018 “Sofosbuvir (SOF)” NCT02421211 ↗ “sofosbuvir (SOF)” PMID 30598598 ↗ Nov 2018 “sofosbuvir (SOF)” NCT02723084 ↗ “sofosbuvir (SOF)” NCT02399345 ↗ |
| Known as | Sofosbuvir (GS-7977) | “Sofosbuvir (GS-7977)” NCT01805882 ↗ |
| Known as | Sofosbuvir component of epclusa | ChEMBL registry synonym — accepted as the source's own label CHEMBL1259059 ↗ |
| Known as | Sofosbuvir component of harvoni | ChEMBL registry synonym — accepted as the source's own label CHEMBL1259059 ↗ |
| Known as | Sofosbuvir component of vosevi | ChEMBL registry synonym — accepted as the source's own label CHEMBL1259059 ↗ |
| Known as | Sofosbuvir/ Ledipasvir | “This study aims to evaluate the safety and efficacy of the combined Sofosbuvir/ Ledipasvir regimen given for 12 weeks in children aged 12-18 years or weighing at least 35 kg...” NCT05091008 ↗ |
| Known as | Solvaldi (Sofosbuvir); | “Solvaldi (Sofosbuvir);” NCT02455167 ↗ |
| Known as | sovaldi | “Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per...” NCT03146741 ↗7“Sofosbuvir (SOVALDI®) is a nucleotide analog directed against HCV NS5B polymerase, clinically approved with potent antiviral effects on the hepatitis C virus with several genotypes21.” NCT04468087 ↗ “daily oral 400 mg SOF ( (Sovaldi, Gilead Sciences, Inc., USA), RBV (Copegus, Roche, Europe) based on body weight” NCT04382339 ↗ “using 12 weeks of Olysio/Sovaldi/Ribavirin (or known as: Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin (RBV).” NCT02455167 ↗ “treated with Sofosbuvir 400 mg (Sovaldi) + Daclatasvir 60mg (Daklinza) + Ribavirin 200 mg (Rebetol)” NCT03547895 ↗ “SOVALDI (Sofosbuvir) (400mg QD)” NCT02214420 ↗ “Sofosbuvir 400 MG [Sovaldi]” NCT03312023 ↗ “Sofosbuvir, Sovaldi” NCT02304159 ↗ |
| Known as | Sovaldi (sofosbuvir) | “Sovaldi (sofosbuvir)” NCT01532908 ↗ |
| Known as | Sovaldi is a trade name of sofosbuvir | “Sovaldi is a trade name of sofosbuvir” NCT04387539 ↗1“Sovaldi is a trade name of sofosbuvir” NCT04385407 ↗ |
| Action | Inhibit | “nucleotide polymerase inhibitor sofosbuvir” PMID 24262278 ↗ Nov 2013 |
| Modality | Small molecule | “sofosbuvir, a uridine nucleotide analogue” PMID 23499158 ↗ Mar 2013 |
| Route | Oral | “Sofosbuvir tablet(s) administered orally once daily” NCT01054729 ↗ |